Azza Omar Malaysia

Senior Consultant, Respiratory & General Medicine Hospital Raja Perempuan Zainab II, Malaysia Dr. Azza Omar is a Senior Consultant in the Department of Respiratory and General Medicine at Hospital Raja Perempuan Zainab II, Malaysia. She graduated from Universiti Sains Malaysia in 1999 and obtained her Master of Internal Medicine in 2008 before pursuing fellowship training in Respiratory Medicine. Her clinical and research interests include severe asthma, airway diseases, COPD, and lung cancer, with a strong focus on multidisciplinary respiratory care and biologic therapy. She established the multidisciplinary Severe Asthma Clinic at Hospital Raja Perempuan Zainab II in 2018, making the center one of the pioneer severe asthma referral centers in Malaysia. Dr. Azza is actively involved in national respiratory initiatives and was part of the Malaysian “Severe Asthma Working Group,” contributing to the development of educational resources and guidance for establishing severe asthma services nationwide. She also contributes to the development of Malaysian Asthma Guidelines and participated in the 2024 APSR Asthma Position Statement update. She is also recently being appointed as the chair for Malaysia Lung Cancer Guidelines. Beyond clinical practice, she is actively involved in medical education through the Respiratory Fellowship training programme and serves as an Adjunct Professor at Lincoln University College Medical School. She is a frequent invited speaker, chairperson, and faculty member at national and regional respiratory conferences, with multiple academic collaborations and publications in respiratory medicine.
Job Title
Consultant Respiratory Physician
Faculty / Department / Division
Medical Department
Institution / Organisation
Raja Perempuan Zainab II Hospital

20 November 2026, Friday

Time Session
11:00
12:00
Aisya Natasya Musa Chairperson Malaysia
Diahn-Warng Perng Chairperson Taiwan
  • Azza Omar Speaker Malaysia
  • Anthony Yii Speaker Singapore
    Acute asthma exacerbations are conventionally treated with a standard course of systemic corticosteroids, regardless of the underlying inflammatory phenotype. However, increasing evidence suggests that exacerbations are biologically heterogeneous, with differences in corticosteroid responsiveness between type 2-high and type 2-low inflammation. Repeated corticosteroid exposure also contributes to substantial long-term morbidity and healthcare costs. This presentation examines the rationale and emerging evidence for biomarker-directed treatment of acute asthma exacerbations. Transcriptomic studies demonstrate differential corticosteroid effects across inflammatory pathways, while clinical studies suggest that physiological responses may vary according to inflammatory phenotype. Findings from a randomized controlled trial evaluating blood eosinophil-guided corticosteroid duration in hospitalized asthma exacerbations will be presented, alongside emerging evidence for biologic therapies during acute exacerbations. Together, these findings support a shift towards more individualized exacerbation management, with the potential to reduce unnecessary corticosteroid exposure while maintaining clinical effectiveness. Larger confirmatory trials are needed before widespread implementation.
  • Peter Gibson Speaker Australia
  • Q&A
Ballroom 1, Lower Ground Floor

21 November 2026, Saturday

Time Session
12:30
13:30
Sponsored by AstraZeneca
Azza Omar Chairperson Malaysia
Ballroom 2, Lower Ground Floor

22 November 2026, Sunday

Time Session
12:00
13:00
Azza Omar Chairperson Malaysia
  • Naoya Tanabe Speaker Japan
    Sarcopenia is an important extrapulmonary manifestation of chronic obstructive pulmonary disease (COPD), contributing to reduced physical function and adverse clinical outcomes. Updated Asian Working Group for Sarcopenia (AWGS) 2025 criteria provide a framework for its assessment. Chest computed tomography (CT) enables evaluation of skeletal muscle quantity and quality, offering additional prognostic information. Particularly, reduced erector spinae muscle density, reflecting intramuscular fat accumulation, is associated with loss of health-related independence, in patients with normal body weight. Recent studies have also demonstrated an association between airway mucus plugging and sarcopenia in COPD. Greater mucus plug burden is associated with reduced exercise capacity, skeletal muscle mass, and fat mass, suggesting potential interactions between pulmonary and systemic impairment. These findings highlight the importance of comprehensive assessment beyond airflow limitation. Early identification of sarcopenia and integrated interventions targeting physical activity, nutrition, and respiratory health may improve long-term outcomes in COPD.
  • Pui Ching Shirley Ngai Speaker Hong Kong
    Chronic obstructive pulmonary disease (COPD) is frequently complicated by sarcopenia, a debilitating condition characterized by the accelerated loss of skeletal muscle mass and functional capacity. Compared with their healthy counterparts, individuals with COPD have a higher prevalence of developing sarcopenia. This disproportionate burden is driven by distinct, disease-specific biological mechanisms. Notably, COPD induces a structural muscle fiber shift from fatigue-resistant oxidative fibers (Type I) to force-predominant glycolytic fibers (Type II). This metabolic shift is fundamentally compounded by decreased capillarization and prominent intramuscular fat infiltration, which collectively compromise oxidative capacity and accelerate functional decline. Previous studies suggest that targeted nutritional intervention is critical in managing this complex phenotype, yet standard dietary guidelines routinely fall short. This presentation summarises the clinical recommendations and discusses how the nutritional supplementation would help and support the management for people with COPD.
  • Soo Chin Chan Speaker Malaysia
    This presentation explores sarcopenia in COPD from a rehabilitation perspective, focusing on how COPD affects skeletal muscle and how exercise training can modify these changes. It highlights the complementary roles of resistance and endurance training, before considering how pulmonary rehabilitation translates physiological improvements into better function and participation. The key message is that exercise targets the muscle, while rehabilitation helps translate these gains into what matters to the patient.
  • Q&A
Ballroom 3, Lower Ground Floor